Table 2.
Distribution of first-time regimen change by individual category at JH from September 2006 to August 2016.
| Initial ART regimen | Initial regimen changed to (%) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| d4T-based |
AZT-based |
TDF-based |
ABC-based |
Total | ||||||
| d4T/3TC/NVP | d4T/3TC/EFV | AZT/3TC/NVP | AZT/3TC/EFV | TDF/3TC/EFV | TDF/3TC/NVP | TDF/3TC/LPV/r | TDF/3TC/ATZ/r | ABC/3TC/LPV/r | ||
| d4T/3TC/NVP | – | 25 (21.19) | a | 20 (16.95) | 67 (56.78) | a | 3 (2.54) | 1 (0.85) | 2 (1.69) | 118 (53.63) |
| d4T/3TC/EFV | 3 (17.65) | – | 3 (17.65) | a | a | 6 (35.29) | 4 (23.53) | 0 | 1 (5.88) | 17 (7.72) |
| AZT/3TC/NVP | 0 | 0 | – | 11 (32.35) | 13 (38.24) | 7 (20.59) | 3 (8.82) | 0 | 0 | 34 (15.45) |
| AZT/3TC/EFV | 1 (3.57) | 0 | 3 (10.71) | – | 20 (71.43) | 1 (3.57) | 1 (3.57) | 1 (3.57) | 1 (3.57) | 28 (12.72) |
| TDF/3TC/EFV | 0 | 0 | 0 | 0 | – | 4 (57.14) | 1 (14.28) | 1 (14.28) | 1 (14.28) | 7 (3.18) |
| TDF/3TC/NVP | 0 | 1 (6.25) | 0 | 0 | 11 (68.75) | – | 2 (12.5) | 0 | 2 (12.5) | 16 (7.27) |
| Total | 4 (1.82) | 26 (11.82) | 6 (2.73) | 31 (14.09) | 111 (50.45) | 18 (8.82) | 14 (6.36) | 3 (1.36) | 7 (3.18) | 220 |
TDF: tenofovir disoproxil fumarate; d4T: stavudine; AZT: zidovudine; ABC: abacavir.
a
Mere change of d4T was omitted.